DOP2006000088A - Compuestos utiles en terapia - Google Patents

Compuestos utiles en terapia

Info

Publication number
DOP2006000088A
DOP2006000088A DO2006000088A DO2006000088A DOP2006000088A DO P2006000088 A DOP2006000088 A DO P2006000088A DO 2006000088 A DO2006000088 A DO 2006000088A DO 2006000088 A DO2006000088 A DO 2006000088A DO P2006000088 A DOP2006000088 A DO P2006000088A
Authority
DO
Dominican Republic
Prior art keywords
alkyl
optionally substituted
halo
cycloalkyl
het
Prior art date
Application number
DO2006000088A
Other languages
English (en)
Inventor
Paul Antony Bradley
Kevin Neil Dack
Ian Roger Marsh
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of DOP2006000088A publication Critical patent/DOP2006000088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de formula (I), o derivadosfarmacéuticamente aceptables de los mismos, en la que: R1 representa H, alquilo C1_6, alquil C1-6-oxi, cicloalquilo C3_8 o halo; R2 representa H, alquilo C1_6 (opcionalmente sustituido con R3), fenilo (opcionalmente sustituido con CN) o Het; R3 representa OH, CN, Het; -R4-alquilo C1-6 o CONR5R6; R4 representa -CO2- o -0-; R5 y R6 representan independientemente H, alquilo C1-6 (opcionalmente sustituido con OR7) o cicloalquilo C3_8; R7 representa H o alquilo C1-6; Het representa un grupo heterocíclico aromático de cinco o seis miembros que contiene (i) de uno a cuatro heteroátomo(s) de nitrógeno o (ii) uno o dos heteroátomo(s) de nitrógeno y un heteroátomo de oxígeno o uno de azufre o (iii) uno o dos heteroátomos(s) de oxígeno o azufre, estando dicho grupo heterocíclico opcionalmente sustituido con uno o más grupos seleccionados entre CN y alquilo C1_6; R8 representa alquilo C1_6, alquil C1_6-oxi, cicloalquilo C3_8 o halo; R9 y R10 representan independientemente H, alquilo C1_6, alquil C1_6-oxi, CN, CF3 o halo; pueden ser útiles para tratar endometriosis, fibroides uterinos (leiomiomata), menorragia, adenomiosis, dismenorrea primaria y secundaria
DO2006000088A 2005-04-20 2006-04-11 Compuestos utiles en terapia DOP2006000088A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67354405P 2005-04-20 2005-04-20

Publications (1)

Publication Number Publication Date
DOP2006000088A true DOP2006000088A (es) 2006-10-31

Family

ID=35044974

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000088A DOP2006000088A (es) 2005-04-20 2006-04-11 Compuestos utiles en terapia

Country Status (12)

Country Link
US (2) US7482375B2 (es)
EP (1) EP1874732A1 (es)
JP (1) JP2008536910A (es)
AR (1) AR053587A1 (es)
CA (1) CA2604218A1 (es)
DO (1) DOP2006000088A (es)
GT (1) GT200600155A (es)
NL (1) NL1031626C2 (es)
PE (1) PE20061316A1 (es)
TW (1) TW200716609A (es)
UY (1) UY29486A1 (es)
WO (1) WO2006111856A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003167A1 (en) 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US20100087407A1 (en) * 2006-08-04 2010-04-08 James Symons use of aromatase inhibitors
US20080096950A1 (en) * 2006-10-19 2008-04-24 Karl Richard Gibson Compounds Useful In Therapy
PE20081803A1 (es) * 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
WO2008135824A1 (en) * 2007-05-02 2008-11-13 Pfizer Limited Oxyalkylpyrazole compounds useful in therapy
US20100292150A1 (en) * 2007-12-10 2010-11-18 Meditrina Pharmaceuticals, Inc. Treatment of Menorrhagia with Aromatase Inhibitor
AR071069A1 (es) * 2008-03-26 2010-05-26 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
MX2011002899A (es) 2008-09-18 2011-04-11 Pfizer Ltd Compuestos de amida utiles en terapia.
US20150272622A1 (en) * 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
ES2701400T3 (es) 2012-05-31 2019-02-22 Repros Therapeutics Inc Formulaciones para la administración vaginal de antiprogestinas
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
WO2015171392A1 (en) * 2014-05-06 2015-11-12 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
WO2016081383A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621024C2 (de) * 1986-06-20 1999-10-28 Schering Ag 11beta-Phenylestradiene, deren Herstellung und diese enthaltende pharmazeutische Präparate
PT1762567E (pt) * 2001-04-10 2012-07-16 Pfizer Derivados de pirazole para tratamento do vih
US6933312B2 (en) * 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives

Also Published As

Publication number Publication date
US20060241125A1 (en) 2006-10-26
TW200716609A (en) 2007-05-01
GT200600155A (es) 2007-04-18
WO2006111856A1 (en) 2006-10-26
JP2008536910A (ja) 2008-09-11
PE20061316A1 (es) 2007-01-13
AR053587A1 (es) 2007-05-09
NL1031626A1 (nl) 2006-10-23
NL1031626C2 (nl) 2007-03-19
UY29486A1 (es) 2006-11-30
US20090099209A1 (en) 2009-04-16
US7482375B2 (en) 2009-01-27
EP1874732A1 (en) 2008-01-09
CA2604218A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
DOP2006000088A (es) Compuestos utiles en terapia
DOP2006000245A (es) Compuestos útiles en terapia
HRP20080608T3 (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
CO5640041A2 (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias
ECSP088150A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR062928A1 (es) Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2
AR042586A1 (es) 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
AR054882A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
AR032621A1 (es) Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos
DK0650961T3 (da) Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
NO20035316D0 (no) Tiazol- eller oksazol-derivater som er anvendelige ved behandling av kardiovaskul¶re og beslektede sykdommer
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
CO5690585A2 (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
CO5650165A2 (es) Procedimientos para la preparacion de derivados de benzoimidazol
WO2005080357A3 (fr) Derives d’oxazole, leur preparation et leur utilisation en therapeutique
DE3868301D1 (de) 2-(methyl(4-piperidinyl))-1,2,3,4-tetrahydro-9h-pyrido(3,4-b)indolderivate, ihre herstellung und therapeutische verwendung.
HUP0201834A2 (hu) Thyromimetikus vegyületek alkalmazása hajhullás kezelésére szolgáló gyógyszerkészítmény előállítására és ilyen készítmények
AR032775A1 (es) Procedimiento para la preparacion de imidazotriazinonas sustituidas con sulfonamida
CO4970752A1 (es) Nuevos derivados de isatin y composiciones farmaceuticas conteniendo tales isatines
YU48335B (sh) Novi 1-aril-5-(supstituisani alkilidenimino)pirazoli,postupci za njihovu proizvodnju i pesticidne smeše koje ih sadrže
RS50642B (sr) Derivati triazolopiridinilsulfanila kao inhibitori p38 map kinaze
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
PE20020708A1 (es) 2-piridonas antimicrobianas, sus composiciones y usos
EA200700322A1 (ru) Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов